Skip to main content
. 2021 Apr 11;11(4):338. doi: 10.3390/life11040338

Figure 4.

Figure 4

Anti-HBcN15 serum does not neutralise FMDV but does recognise virus particles (A) Plaque reduction neutralisation assays were carried out to assess the effect of anti-HBcN15 serum on virus infectivity. Data plotted represent mean of triplicate wells and error bars indicate standard deviation. (B) Sandwich ELISAs using bovine αvβ6 integrin as the capture were used to confirm that serum against HBcN15 recognised FMDV virus particles.